{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:43:41Z","timestamp":1768279421782,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["#MOP-12344"],"award-info":[{"award-number":["#MOP-12344"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ontario Graduate Scholarships"},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.coph.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,8,28]],"date-time":"2016-08-28T05:45:26Z","timestamp":1472363126000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Current and potential therapeutic targets of glucagon-like peptide-2"],"prefix":"10.1016","volume":"31","author":[{"given":"Kaori","family":"Austin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie A","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L","family":"Brubaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2016.08.008_bib0265","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2016.08.008_bib0270","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00039.2011","article-title":"The \u201ccryptic\u201d mechanism of action of glucagon-like peptide-2","volume":"301","author":"Rowland","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_sbref0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.coph.2016.08.008_sbref0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MED.0000000000000120","article-title":"Gut hormones in the treatment of short-bowel syndrome and intestinal failure","volume":"22","author":"Jeppesen","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.coph.2016.08.008_bib0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0016-5085(99)70555-X","article-title":"Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans","volume":"117","author":"Xiao","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0290","doi-asserted-by":"crossref","first-page":"G662","DOI":"10.1152\/ajpgi.1997.272.3.G662","article-title":"Biological determinants of intestinotrophic properties of GLP-2 in vivo","volume":"272","author":"Tsai","year":"1997","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0295","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2009.05.057","article-title":"ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut","volume":"137","author":"Yusta","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0300","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.gastro.2006.05.055","article-title":"Essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice","volume":"131","author":"Dube","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0305","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1210\/en.2016-1127","article-title":"Glucagon-like peptide-2 requires a full-complement of Bmi-1 for its proliferative effects in the murine small intestine","volume":"157","author":"Smither","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.08.008_bib0310","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2184.2004.00320.x","article-title":"Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage","volume":"37","author":"Booth","year":"2004","journal-title":"Cell Prolif"},{"key":"10.1016\/j.coph.2016.08.008_bib0315","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1053\/j.gastro.2011.09.014","article-title":"Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1 receptor deletion","volume":"141","author":"Rowland","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_sbref0320","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1210\/en.2014-1829","article-title":"IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestine","volume":"156","author":"Austin","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.08.008_bib0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.regpep.2004.07.009","article-title":"GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors","volume":"124","author":"Orskov","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.coph.2016.08.008_bib0330","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1096\/fj.14-264010","article-title":"IGF1 stimulates crypt expansion via differential activation of 2 intestinal stem cell populations","volume":"29","author":"Van Landeghem","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2016.08.008_bib0335","first-page":"1157","article-title":"Insulin-like growth factor-I and epidermal growth factor interact to regulate growth and gene expression in IEC-6 intestinal epithelial cells","volume":"9","author":"Simmons","year":"1995","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2016.08.008_bib0340","doi-asserted-by":"crossref","first-page":"E937","DOI":"10.1152\/ajpendo.1999.277.5.E937","article-title":"Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis","volume":"277","author":"Boushey","year":"1999","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.coph.2016.08.008_bib0345","first-page":"687","article-title":"Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor","volume":"61","author":"Boushey","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2016.08.008_bib0350","first-page":"G79","article-title":"Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis","volume":"276","author":"Drucker","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0355","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gut.47.1.112","article-title":"Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse","volume":"47","author":"Benjamin","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.coph.2016.08.008_bib0360","doi-asserted-by":"crossref","first-page":"G914","DOI":"10.1152\/ajpgi.00005.2011","article-title":"Proteomic analysis of the enterocyte brush border","volume":"300","author":"McConnell","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0365","first-page":"E1050","article-title":"Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2","volume":"272","author":"Brubaker","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0370","doi-asserted-by":"crossref","first-page":"G911","DOI":"10.1152\/ajpgi.1998.275.5.G911","article-title":"GLP-2 augments the adaptive response to massive intestinal resection in rats","volume":"275","author":"Scott","year":"1998","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_sbref0375","article-title":"Acute effects of a glucagon-like peptide 2 analogue, teduglutide, on gastrointestinal motor function and permeability in adult patients with short bowel syndrome on home parenteral nutrition","author":"Iturrino","year":"2015","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.coph.2016.08.008_bib0380","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2009.05.051","article-title":"Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36","volume":"137","author":"Hsieh","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0385","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1210\/EN.2015-1110","article-title":"Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and postabsorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice","volume":"156","author":"Hsieh","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.08.008_sbref0390","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2014.08.037","article-title":"Glucagon-like peptide-2 regulates release of chylomicrons from the intestine","volume":"147","author":"Dash","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0395","doi-asserted-by":"crossref","first-page":"R1965","DOI":"10.1152\/ajpregu.1997.273.6.R1965","article-title":"Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo","volume":"273","author":"Cheeseman","year":"1997","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0400","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/bj20020393","article-title":"Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2","volume":"367","author":"Au","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.coph.2016.08.008_bib0405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.regpep.2011.03.003","article-title":"The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients","volume":"168","author":"Bremholm","year":"2011","journal-title":"Regul Pept"},{"key":"10.1016\/j.coph.2016.08.008_bib0410","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2005.11.005","article-title":"GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow","volume":"130","author":"Guan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0415","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.coph.2016.08.008_bib0420","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1210\/en.2013-1871","article-title":"The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function","volume":"155","author":"Dong","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.08.008_bib0425","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00530.2006","article-title":"Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2","volume":"293","author":"Sigalet","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2015.07.025","article-title":"The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitis","volume":"75","author":"Nakame","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.coph.2016.08.008_bib0435","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1177\/0148607114525210","article-title":"Intestinal adaptation following resection","volume":"38","author":"Tappenden","year":"2014","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.coph.2016.08.008_bib0440","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14728222.2016.1146695","article-title":"On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome","volume":"20","author":"Lim","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.coph.2016.08.008_bib0445","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-like peptide 2 improves nutrient absorption and nutritional status in Short-Bowel patients with no colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2016.08.008_bib0450","first-page":"425751","article-title":"Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life","volume":"2009","author":"Jeppesen","year":"2009","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.coph.2016.08.008_bib0455","first-page":"616051","article-title":"Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function","volume":"2009","author":"Jeppesen","year":"2009","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.coph.2016.08.008_bib0460","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.coph.2016.08.008_bib0465","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.clnu.2013.03.016","article-title":"Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide\u2014analyses from a randomised, placebo-controlled study","volume":"32","author":"Jeppesen","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1016\/j.coph.2016.08.008_bib0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.regpep.2013.03.025","article-title":"Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study","volume":"184","author":"Madsen","year":"2013","journal-title":"Regul Pept"},{"key":"10.1016\/j.coph.2016.08.008_bib0475","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1210\/en.2009-0295","article-title":"Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice","volume":"150","author":"Iakoubov","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2016.08.008_bib0480","doi-asserted-by":"crossref","first-page":"G840","DOI":"10.1152\/ajpgi.00505.2011","article-title":"Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer","volume":"302","author":"Trivedi","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0485","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/pr.2014.97","article-title":"Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome","volume":"76","author":"Suri","year":"2014","journal-title":"Pediatr Res"},{"key":"10.1016\/j.coph.2016.08.008_sbref0490","doi-asserted-by":"crossref","DOI":"10.1177\/0148607115609566","article-title":"A safety and dosing study of glucagon-like peptide 2 in children with intestinal failure","author":"Sigalet","year":"2015","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.coph.2016.08.008_bib0495","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ibd.21117","article-title":"Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease","volume":"16","author":"Buchman","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2016.08.008_bib0500","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.105.085373","article-title":"Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2","volume":"314","author":"Cameron","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2016.08.008_bib0505","doi-asserted-by":"crossref","first-page":"R1794","DOI":"10.1152\/ajpregu.90616.2008","article-title":"Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats","volume":"295","author":"Liu","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.coph.2016.08.008_bib0510","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1586\/17474124.2016.1124759","article-title":"Refractory celiac disease","volume":"10","author":"Rishi","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2016.08.008_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/dmm.022269","article-title":"The role of enterocyte defects in the pathogenesis of congenital diarrheal disorders","volume":"9","author":"Overeem","year":"2016","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.coph.2016.08.008_bib0520","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpg.2009.10.009","article-title":"Small intestinal disorders in the elderly","volume":"23","author":"Thomson","year":"2009","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489216300935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T21:09:43Z","timestamp":1568322583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489216300935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":52,"alternative-id":["S1471489216300935"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2016.08.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and potential therapeutic targets of glucagon-like peptide-2","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}